Filing Summary: Fresenius Medical Care AG & Co. KGaA
Business Context and Reporting Period
This Form 6-K, filed on February 21, 2023, reports the fourth-quarter and full-year 2022 financial results for Fresenius Medical Care AG & Co. KGaA. The filing serves to distribute a press release (Exhibit 99.1) and a complete overview of financial figures (Exhibit 99.2) to U.S. investors.
Key Financial Metrics
The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (Exhibit 99.1 and 99.2) referenced in the report.
The Company utilizes the following non-GAAP financial measures to supplement IFRS reporting:
- EBITDA (Operating income excluding interest, taxes, depreciation, and amortization)
- Adjusted EBITDA
- Free Cash Flow
- Net Leverage Ratio (Net debt to adjusted EBITDA)
- Results presented in constant currency
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. Investors must refer to the attached press release and financial overview for comparative analysis.
Guidance, Outlook, and Risks
The filing states that the non-GAAP measures are intended to enhance understanding of current performance and future prospects. It explicitly notes that these measures should not be used as a substitute for GAAP/IFRS financial measures. Reconciliations for EBITDA, Adjusted EBITDA, Net Leverage Ratio, and Free Cash Flow are included in the attached financial statements. The filing does not contain specific guidance, risk factors, or management commentary within the text of the Form 6-K itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2022 revenue and profit figures.
- Examine Exhibit 99.2 for the complete financial overview and reconciliation of non-GAAP measures to IFRS standards.
- Verify the Net Leverage Ratio and Free Cash Flow calculations in the attached exhibits.
- Check for constant currency adjustments to understand organic growth versus currency fluctuation impacts.